Q32 Bio to Participate in Upcoming March Investor Conferences
Q32 Bio (Nasdaq: QTTB), a clinical stage biotechnology company specializing in immune homeostasis therapeutics, has announced its participation in two major investor conferences this March.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Q32 Bio (Nasdaq: QTTB), a clinical stage biotechnology company specializing in immune homeostasis therapeutics, has announced its participation in two major investor conferences this March.
The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 11:50 a.m. ET, followed by the Leerink Partners Global Healthcare Conference in Miami Beach on March 11, 2025, at 11:20 a.m. ET.
Webcasts of both presentations will be accessible through Q32 Bio's website, with replays available for 90 days after the events.
Details
News Market Reaction – QTTB
The recorded move for QTTB in the trading session of this news was -5.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TD Cowen 45th Annual Health Care Conference
Date: Wednesday, March 5, 2025
Presentation Time: 11:50 a.m. E.T.
Location:
Leerink Partners Global Healthcare Conference
Date: Tuesday, March 11, 2025
Fireside Chat Presentation Time: 11:20 a.m. E.T.
Location:
A webcast of the presentations will be available on the Events and Presentations page of Q32 Bio's website at www.Q32Bio.com. Archived replays will be available for 90 days following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases.
Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases being evaluated in a Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-march-investor-conferences-302385199.html
SOURCE Q32 Bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.